

Thursday, 20 February 2025 | special comments

Sygnity: Preliminary 4Q24 Results

Recommendation: sell | target price: PLN 39.00 | current price: PLN 80.00

SGN PW; SGN.WA | IT, Poland

Analyst: Pawel Szpigiel +48 509 603 258

Sygnity yesterday announced its preliminary financial results for 4Q 2024, showing figures well above our expectations. We will be able to comment more fully on the fourth-quarter performance once the full results are out on March 25.

From what we can tell based on data available to date, the 4Q24 results were influenced by earlier acquisitions. It is also worth noting that organic revenue growth in 3Q24 had been fairly weak, indicating that revenues from certain contracts may have been shifted between quarters. Additionally, we suspect that the quarterly results may have been positively impacted by one-time tax-related items (a low tax rate in 4Q). Last but not least, in the latter part of 2024, Sygnity announced having secured several new contracts, including one with the Polish Post Office in September, followed by a deal with the labor ministry in November, which may have provided an additional boost to 4Q24 results.

As mentioned, we will be able to measure organic growth in Sygnity's 4Q24 revenues more precisely once detailed data becomes available. Nevertheless, the preliminary figures reported yesterday turned out more than impressive, which should boost sentiment for Sygnity in the medium term.

- Sygnity estimates its FY2024 revenue at PLN 293.1m.
- EBITDA for the year is expected to come in at PLN 81.7m, which implies that EBITDA margin in 4Q24 reached a very impressive 40% (a level which looks unnaturally high compared to the preceding quarters).
- Full-year profit before tax is estimated at ca. PLN 69.1m, and net profit may amount to PLN 60.4m.
- The two major acquisitions of 2024, Edrana Baltic UAB and Sagra Technology, no doubt continued to influence Sygnity's financial performance in 4Q24, but the Company did not provide specifics of their financial impact in yesterday's preliminary release.

4Q 2024 results of Sygnity

(PLN m)		1Q'23	2Q'23	3Q'23	4Q'23	1Q'24	2Q'24	3Q'24	4Q'24	yoy
Revenue		52.4	51.9	59.2	65.8	62.0	69.5	71.4	90.3	37.3%
COGS		-37.7	-35.4	-38.0	-41.6	-41.7	-46.1	-41.2		
Gross profit		14.7	16.5	21.2	24.2	20.3	23.4	30.1		
	Margin	28.0%	31.8%	35.8%	36.8%	32.7%	33.7%	42.2%		
Selling expenses		-1.6	-1.9	-1.3	-1.8	-1.6	-1.9	-1.6		
Д	s % of sales	3.1%	3.7%	2.2%	2.7%	2.7%	2.7%	2.2%		
Administrative expenses		-7.1	-8.9	-8.6	-7.6	-10.7	-12.2	-12.3		
Д	s % of sales	13.6%	17.1%	14.5%	11.6%	17.3%	17.6%	17.3%		
Other operating activity		0.3	0.4	0.3	0.3	0.4	0.4	0.4		
Profit / (loss) from operations		6.2	6.2	11.6	15.2	8.3	9.7	16.6		
	Margin	11.9%	11.8%	19.7%	23.0%	13.4%	13.9%	23.3%		
Financing activity		-0.1	0.2	-0.2	0.7	-0.1	-0.2	0.1		
Share in result of joint venture		0.0	0.0	0.0	0.0	0.0	0.0	0.0		
Profit / (loss) before tax		6.1	6.4	11.4	15.8	8.2	9.5	16.7	34.8	
Tax		-1.2	-1.3	-2.4	4.4	-0.7	-2.1	-3.1		
Net profit / (loss) from continuing operations		4.9	5.1	9.0	20.2	7.5	7.4	13.5	32.0	58.4%
	Margin	9.4%	9.8%	15.2%	30.7%	12.0%	10.7%	19.0%	35.4%	
EBITDA		8.9	8.8	14.0	17.4	11.3	13.8	20.6	36.0	107.3%
	Margin	16.9%	16.9%	23.6%	26.4%	18.2%	19.9%	28.9%	39.9%	


Source: Sygnity , mBank

2024 full-year preliminary results vs. our expectations

2024 full-year preliminary results vs. our expectations										
(PLN m)	2024	2023 adj.*	y/y	2024E	VS					
Revenue	293.1	229.3	27.8%	288.9	1.5%					
EBITDA	81.7	49.0	66.7%	62.3	31.1%					
EBITDA margin	27.9%	21.4%	-	21.60%	-					
Pre-tax profit	69.1	39.7	74.1%	46.8	47.6%					
Net profit	60.4	39.3	53.7%	38.6	56.5%					

Source: Sygnity E - mBank estimates, *Calendar year. Data compiled from reporting by the Company





Source: Sygnity



List of abbreviations and ratios contained in the report:

EV (Enterprise Value) – Equity Value + Net Debt; EBIT – Earnings Before Interest and Taxes; EBITDA – EBIT + Depreciation & Amortisation; Net Debt – Borrowings + Debt Securities + Interest-Bearing Loans - Cash and Cash Equivalents; P/E (Price/Earnings)) – Price Per Share Divided by Earnings Per Share; P/CE (Price to Cash Flow) – Price Deviation & Amortisation; P/B (Price to Book Value) – Price Per Share Divided by Cash Flow from Operations; APIC (Price to Cash Flow) – Price Deviated by Cash Flow from Operations; APIC (Price to Cash Flow) – EBIT x (Average Equity + Minority Interest + Net Debt); FCFF (Free Cash Flow to Firm) – Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operations - CAPEX - Lease Payments; FCFE (Free Cash Flow to Firm) – Price Per Share Divided by Cash Flow from Operati

OVERWEIGHT (OW) – a rating which indicates that we expect a stock to outperform the broad market NEUTRAL (N) – a rating which indicates that we expect the stock to perform in line with the broad market UNDERWEIGHT (UW) – a rating which indicates that we expect the stock to underperform the broad market

Recommendations of Biuro maklerskie mBanku:

A recommendation is valid for a period of 12 months, unless a subsequent recommendation is issued in this period. Expected returns from individual recommendations are as follows:

BUY - we expect that the rate of return from an investment will be at least 10%

HOLD - we expect that the rate of return from an investment will range from 0% to +10%

SELL - we expect that an investment will bear a loss

The foregoing principle maybe waived where circumstances warrant, including but not limited to periods of increased share price volatility experienced by the company that is the subject of a recommendation immediately preceding the time the recommendation is issued.

Recommendations are updated at least once every twelve months.

mBank S.A. with its registered office in Warsaw at Prosta 18 renders brokerage services via a dedicated organisational unit, the Brokerage Bureau, which uses the Polish name Biuro maklerskie mBanku.

mBank S.A. as part of the Exchange's Analytical Coverage Support Programme ("Programme", https://www.gpw.pl/eacsp) prepares analytical reports for Sygnity. These documents are prepared at the request of Gielda Papierów Wartościowych w Warszawie S.A. ('WSE'), which is entitled to copyrights to these materials. mBank S.A. receives remuneration from the WSE for the preparation of the reports. All documents prepared for the Programme are available at: https://www.mdm.pl/ui-pub/site/market_and_analysis/analysis_and_recommendations/analytical_coverage_support_programme

This document has been created and published by Biuro maklerskie mBanku. The present report expresses the knowledge as well as opinions of the authors on day the report was prepared. The opinions and estimates contained herein constitute our best judgment at this date and time, and are subject to change without notice. The present report was prepared with due care and attention, observing principles of methodological correctness and objectivity, on the basis of sources available to the public, which Biuro maklerskie mBanku considers reliable, including information published by issuers, shares of which are subject to recommendations. However, Biuro maklerskie mBanku, in no case, guarantees the accuracy and completeness of the report, in particular should sources in on the basis of which the report was prepared prove to be inaccurate, incomplete or not fully consistent with the facts. mBank SA bears no responsibility for investment decisions taken on the basis of the present report or for any damages incurred as a result of investment decisions taken on the basis of the present report.

This document does not constitute an offer or invitation to subscribe for or purchase any financial instruments and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. It is being furnished to you solely for your information and may not be reproduced or redistributed to any other person This document does not constitute investment, legal, accounting or other advice, and mBank is not liable for damages resulting from or related to the use of data provided in the documents. This document may not be copied, duplicated and/or be directly or indirectly distributed in the United States, Canada, Australia or Japan, nor transferred to citizens or residents of a state where its distribution may be legally restricted, which does not limit the possibility of publishing materials prepared for the Programme on Sygnity, mBank or WSE websites. Persons who disseminate this document should be aware of the need to comply with such restrictions.

nmendations are based on essential data from the entire history of a company being the subject of a recommendation, with particular emphasis on the period since the previous recommendation.

Investing in shares is connected with a number of risks including, but not limited to, the macroeconomic situation of the country, changes in legal regulations as well as changes on commodity markets. Full elimination of these risks is virtually impossible.
mBank S.A. bears no responsibility for investment decisions taken on the basis of the present report or for any damages incurred as a result of investment decisions taken on the basis of the present report.

It is possible that mBank S.A. in its brokerage activity renders, will render or in the past has rendered services for companies and other entities mentioned in the present report

BM, as a separate organisational unit of the Bank, may buy or sell (or may have bought or sold in the past) the financial instruments discussed herein in the name and on behalf of clients subject to powers of attorney granted by

the clients.
mTFI may hold (or may have held in the past) positions in the financial instruments discussed herein, or in related instruments, held in the investment portfolios of funds operated or managed by mTFI.
The Bank may hold (or may have held in the past) positions in the financial instruments discussed herein, or in related instruments, held in the trading portfolios or banking portfolios managed by the Bank.
The Bank and other members of the Bank's group of companies may hold (or may have held in the past) positions in the financial instruments discussed herein, or in related instruments, held in portfolios they manage.

mBank S.A. does not rule out offering brokerage services to an issuer of securities being the subject of a recommendation

Biuro Maklerskie mBanku S.A. ("BM") has put in place internal regulations governing the active management of conflicts of interest, which establish internal organizational and administrative frameworks and information barrier protocols to prevent and avoid conflicts of interest in connection with recommendations. Different types of brokerage activities are separated from each other within BM's internal organizational structure, including the equity research department, which is separated from other brokerage activities. Information barriers, called "Chinese walls," have been created to restrict the exchange of information between different organizational units and employees of BM.

Information about any conflicts of interest that may arise in connection with the issuance of recommendations (should such a conflict exist) is provided below, and it is valid as of the date of the most recent Monthly Report published by Biuro maklerskie mBanku or as of the date of the most recent recommendation issued for an Issuer, as applicable.

This document was not transferred to the issuers prior to its publication.

Alior Bank SA, Amica SA, Answear.com SA, Bank Handlowy w Warszawie SA, Bank Millennium SA, Bank Polska Kasa Opieki SA, BNPP Bank Polska SA, Captor Therapeutics, CD Projekt SA, Cyber Folks SA, Develia, Erste Group Bank AG, ING Bank Siąski SA, KRUK SA, NEUCA, Powszechna Kasa Oszczędności Bank Polski SA, Powszechny Zakład Ubezpieczeń SA, Raiffeisen Bank International, Santander Bank Polska SA, Sygnity SA, UNIMOT, Wirtualna Polska Holding SA, XTB SA, ZBAKA GROUP SOCIETÉ AMONYME are clients of Bluror maklerskier mBanku.

Alior Bank SA, Amica SA, Answear.com SA, Asseco Poland SA, Atal, Bank Handlowy w Warszawie SA, Bank Millennium SA, Bank Ochrony Środowiska SA, Bank Polska Kasa Opieki SA, BENEFIT SYSTEMS, BNPP Bank Polska SA, Captor Therapeutics, CCC SA, CD Projekt SA, Ciech SA, ComArch SA, Cyber Folks SA, Cyfrowy Polsat SA, Develia, Dino Polska SA, Dom Development, Enea SA, Eurocash SA, Forte SA, Gielda Papierów Wartościowych w Warszawie SA, Crupa Azoty SA, Crupa Kety SA, Grupa Pacuj SA, ING Bank Ślajki SA, Inter Cars SA, Jastrzebska Spólka Weglowa SA, KCHM Polska Miedź SA, Komercni Banka AS, KRUK SA, LPP SA, Mabion, Mo-BRUK SA, Orange Polska SA, ORLEN SA, OTP Bank Nytt, PoE Polska Grupa Energetyczna, Photon Energy NV, Polenergia SA, Powszechna Kasa Oszczędności Bank Polski SA, Powszecha KSA, Powszecha SA, Powszecha SA, Selvita, Shoper SA, Raiffeisen Bank International, Sanok Rubber Company SA, Santander Bank Polska SA, Selvita, Shoper SA, Tauron Polska Energia SA, TEXT, UNIMOT, Vercom SA, VRG SA, Wirtualna Polska Holding SA, XTB SA are clients of mBank SA.

ios SA, BIOCELTIX, Murapol SA, TEN Square Games SA were clients of Biuro maklerskie mBanku/mBank S.A. in the last 12 months

Alior Bank SA, Amica SA, Answear.com SA, Asseco Business Solutions SA, Asseco Poland SA, Atal, Bank Handlowy w Warszawie SA, Bank Millennium SA, Bank Ochrony Środowiska SA, Bank Polska SA, Captor Therapeutics, CCC SA, CD Projekt SA, Ciech SA, Comarch SA, Cyber Folks SA, Cyfrowy Polsat SA, Develia, Dino Polska SA, Dom Development, Enea SA, Erste Group Bank AG, Eurocash SA, Forte SA, Ciech SA, Circha Rayser, SA, Grupa Rety SA, Grupa Pracuj SA, HUUUGE Inc, INC Bank Sigski SA, InPost SA, Inter Cars SA, Jastrzębska Spółka Węglowa SA, KCIMh Polska Miedź SA, KRUK SA, LPP SA, Mabion, Mo-BRUK SA, Murapol SA, NEUCA, Orange Polska SA, ORLEN SA, PCF Group SA, PCE Polska Grupa Energetyczna, Photon Energy NV, PlayWay SA, Polengriga SA, Powszechna Kasa Oszczędności Bank Polski SA, Powszechny Zakład Ubezpieczeń SA, Raiffeisen Bank International, Ryvu Therapeutics SA, Sank Rubber Company SA, Santander Bank Polska SA, Selvita, Shoper SA, Sygnity SA, Tauron Polska Energia SA, TEN Square Games SA, TEXT, UNIMOT, Vercom SA, VRG SA, Wirtualna Polska Holding SA, ZABKA GROUP SOCIÉTÉ ANONYME are counterparties to mBank SA.

The author of this recommendation or another individual who belongs to the same group as the author of this recommendation in the last 12 months has been in charge of managing or co-managing a public offering of Amica SA, Develia, Dino Polska SA, Dom Development, KRUK SA, Santander Bank Polska SA.

mBank S.A. acts as market maker for Develia, Kruk.

mBank S.A., its shareholders and employees may hold long or short positions in the issuers' shares or other financial instruments related to the issuers' shares. mBank, its affiliates and/or clients may conduct or may have conducted transactions for their own account or for account of another with respect to the financial instruments mentioned in this report or related investments before the recipient has received this report.

Copying or publishing the present report, in full or in part, or disseminating in any way information contained in the present report requires the prior written agreement of mBank S.A. Recommendations are addressed to all Clients of Biuro maklerskie mBanku.

mmendations are addressed to all Clients of Biuro maklerskie mBanku.

All investment recommendations and strategies issued by mBank S.A. over the last 12 months are available at: https://mdm.pi/bm/analizy

The activity of mBank S.A. is subject to the supervision of the Polish Financial Supervision Commission

Individuals who did not participate in the preparation of recommendations, but had or could have had access to recommendations prior to their publication, are employees of Biuro maklerskie mBanku authorised to access the premises in which recommendations are prepared and/or individuals having to access to recommendations based on their corporate roles, other than the analysts mentioned as the authors of the present recommendations.

This publication constitutes investment research within the meaning of Art. 36.1 of Commission Delegated Regulation (EU) 2017/565.

The compensation of the research analysts responsible for preparing investment research is determined independently of and without regard to the compensation of or revenue generated by any other employee of the Bank, including but not limited to any employee whose business interests may reasonably be considered to conflict with the interests of the persons to whom the investment research prepared by the Research Department of Biuro maklerskie melanku is disseminated. With that being said, since one of the factors taken into consideration when determining the compensation of research analysts is the degree of fulfillment of annual financial targets by customer service functions, there is a risk that the adequacy of compensation offered to persons preparing investment research will be questioned by a competent oversight body.

For U.S. persons only: This research report is a product of mBank SA which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by u.S. broker-dealer, and is/are not required to cateful required to statisfy the regulatory licensing requirements of FINIRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research

incertaing requirements or interA or required to otherwise comply with U.S. rules or regulations regarding, among other timings, communications with a subject company, public appearances and trading securities enal by a research analyst account.

This report is intended for distribution by mBank SA only to "Major Institutional Investors" as defined by Rule 15a-6(pl(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, mBank SA has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

ong and weak points of valuation methods used in recommendations:

- acknowledged as the most methodologically correct method of valuation; it consists in discounting financial flows generated by a company; its weak point is the significant susceptibility to a change of for

in the model.

Relative - based on a comparison of valuation multipliers of companies from a given sector; simple in construction, reflects the current state of the market better than DCF; weak points include substantial variability (fluctuations together with market indices) as well as difficulty in the selection of the group of comparable companies.

Economic profits - discounting of future economic profits; the weak point is high sensitivity to changes in the assumptions made in the valuation model.

Discounted Dividends (DDM) - discounting of future dividends; the weak point is high sensitivity to changes in the assumptions as to future dividends made in the valuation model.

NAV - valuation based on equity value, one of the most frequently used method in case of developing companies; the weak point of the method is that it does not factor in future changes in revenue/profits of a company.



mBank S.A.

Prosta 18 00-850 Warszawa http://www.mbank.pl/

Research Department

Kamil Kliszcz director +48 667 770 837 kamil.kliszcz@mbank.pl energy, power generation

Michał Konarski +48 515 025 640 michal.konarski@mbank.pl banks, financials

Janusz Pięta +48 506 065 659 janusz.pieta@mbank.pl retail, e-commerce Mateusz Krupa, CFA deputy director +48 571 608 973 mateusz.krupa@mbank.pl strategy

Mikołaj Lemańczyk, CFA +48 501 663 511 mikolaj.lemanczyk@mbank.pl banks, financials, property developers

Beata Szparaga-Waśniewska, CFA +48 510 929 021 beata.szparaga-wasniewska@mbank.pl biotechnology, healthcare Paweł Szpigiel +48 509 603 258 pawel.szpigiel@mbank.pl media, IT, telco, e-commerce

Piotr Poniatowski +48 509 603 046 piotr.poniatowski@mbank.pl gaming, leisure

Jakub Sargsyan +48 519 419 895 marlen.sargsyan@mbank.pl industrials, mining

Sales and Trading

Traders

Piotr Gawron director +48 698 832 853 | +48 22 697 48 95 piotr.gawron@mbank.pl

Andrzej Kowalczyk +48 789 868 634 | +48 22 697 47 44 andrzej.kowalczyk@mbank.pl

Karol Kułaj +48 509 602 984 | +48 22 697 49 85 karol.kulaj@mbank.pl

Sales, Foreign Markets

Marzena Łempicka-Wilim deputy director +48 696 427 249 | +48 22 697 48 82 marzena.lempicka-wilim@mbank.pl Paweł Cylkowski +48 503 684 130 | +48 22 697 47 31 pawel.cylkowski@mbank.pl

Andrzej Sychowski +48 605 848 003 | +48 22 697 48 46 andrzej.sychowski@mbank.pl Piotr Brożyna +48 512 756 702 | +48 22 697 48 47 piotr.brozyna@mbank.pl

Łukasz Płaska +48 784 449 962 | +48 22 697 47 90 lukasz.plaska@mbank.pl

Private Client Sales

Maciej Sokołowski director maciej.sokolowski@mbank.pl Jarosław Banasiak deputy director jaroslaw.banasiak@mbank.pl